ReACp53 is primarily used in research focused on cancer therapy. It works by targeting and inhibiting the aggregation of mutant p53 proteins, which are often implicated in various cancers. By preventing these proteins from clumping together, ReACp53 helps restore normal p53 function, thereby promoting cancer cell death and inhibiting tumor growth. This makes it a promising candidate for developing treatments for cancers where p53 mutations play a critical role. Additionally, it is utilized in studies exploring protein misfolding diseases, offering insights into therapeutic strategies for conditions linked to protein aggregation.